We have located links that may give you full text access.
Systematic review and network meta-analysis Medical therapies to prevent recurrence of post-operative Crohn's disease.
Journal of Crohn's & Colitis 2018 December 15
Background and Aims: Surgery is an important treatment for Crohn's disease (CD) but recurrence occurs in up to 80% of individuals post-operatively. The efficacy of several drugs to prevent post-operative recurrence has been studied in previous meta-analyses, but a number of randomised controlled trials (RCTs) have recently been published. We therefore performed an updated systematic review and network meta-analysis to investigate this issue.
Methods: We performed a comprehensive literature search through to July 2018 to identify RCTs investigating the endoscopic and clinical recurrence of CD at 12 months post-operatively. We performed a random-effects network meta-analysis to produce a pooled relative risk (RR) with 95% confidence intervals (CIs). We ranked the treatments according to their P-score.
Results: We included ten RCTs, containing 751 patients, in our primary analysis of endoscopic recurrence of CD at 12 months. Anti-tumour necrosis factor (TNF)-α therapies were significantly better than placebo, either alone (P-score 0.98, RR 0.13; 95% CI 0.04 to 0.39) or in combination with 5-aminosalicylates (5-ASAs) (P-score 0.81, RR 0.30; 95% CI 0.12 to 0.75), or 5-nitroimidazoles (P-score 0.75, RR 0.40; 95% CI 0.23 to 0.69). Combination therapy with a thiopurine and 5-nitroimidazole was also more effective than placebo (P-score 0.59, RR 0.56; 95% CI 0.40 to 0.80), as was thiopurine monotherapy (P-score 0.31, RR 0.84; 95% CI 0.74 to 0.94). However, neither 5-nitroimidazoles nor 5-ASAs alone were superior to placebo.
Conclusions: In network meta-analysis anti-TNF-α therapies alone, or in combination, appear to be the best medications for preventing endoscopic post-operative recurrence of CD.
Methods: We performed a comprehensive literature search through to July 2018 to identify RCTs investigating the endoscopic and clinical recurrence of CD at 12 months post-operatively. We performed a random-effects network meta-analysis to produce a pooled relative risk (RR) with 95% confidence intervals (CIs). We ranked the treatments according to their P-score.
Results: We included ten RCTs, containing 751 patients, in our primary analysis of endoscopic recurrence of CD at 12 months. Anti-tumour necrosis factor (TNF)-α therapies were significantly better than placebo, either alone (P-score 0.98, RR 0.13; 95% CI 0.04 to 0.39) or in combination with 5-aminosalicylates (5-ASAs) (P-score 0.81, RR 0.30; 95% CI 0.12 to 0.75), or 5-nitroimidazoles (P-score 0.75, RR 0.40; 95% CI 0.23 to 0.69). Combination therapy with a thiopurine and 5-nitroimidazole was also more effective than placebo (P-score 0.59, RR 0.56; 95% CI 0.40 to 0.80), as was thiopurine monotherapy (P-score 0.31, RR 0.84; 95% CI 0.74 to 0.94). However, neither 5-nitroimidazoles nor 5-ASAs alone were superior to placebo.
Conclusions: In network meta-analysis anti-TNF-α therapies alone, or in combination, appear to be the best medications for preventing endoscopic post-operative recurrence of CD.
Full text links
Related Resources
Trending Papers
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies.Journal of Personalized Medicine 2024 Februrary 4
Molecular Targets of Novel Therapeutics for Diabetic Kidney Disease: A New Era of Nephroprotection.International Journal of Molecular Sciences 2024 April 4
Perioperative echocardiographic strain analysis: what anesthesiologists should know.Canadian Journal of Anaesthesia 2024 April 11
The 'Ten Commandments' for the 2023 European Society of Cardiology guidelines for the management of endocarditis.European Heart Journal 2024 April 18
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app